Under construction – not a live service
Sign in
Taking people in SwitzerlandNo phase

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

Key facts

Where
Aarau, SwitzerlandSee the site

Where in Switzerland

  • Kantonsspital AarauAarau, SwitzerlandTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Bristol-Myers Squibb
Trial code
NCT06357754
Record updated
22 January 2026
Original description
The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.Read full original descriptionShow less

Protocol for Transgene Assay Service

The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.

Inclusion: Participant has received a commercially available Bristol-Myers Squibb (BMS) manufactured Gene Modified Cell Therapy (GMCT) and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing; Participant has received a commercially available BMS manufactured GMCT in a clinical trial or other investigational setting (including non-conforming product) for which there is no testing protocol in place for that trial or investigational setting and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing.

Exclusion: Participant has not received a BMS manufactured GMCT or has not been diagnosed with a qualifying second primary malignancy; Participant is actively participating in a clinical trial where information and sample collection is being conducted under that clinical trial.

ClinicalTrials.gov NCT06357754